Summary

The Healthcare analytical testing services Market is projected to reach USD 12.6 billion by 2029 from USD 7.4 billion in 2024, at a CAGR of 11.2% during the forecast period. The growth of the healthcare analytical testing services market is fueled by increasing demand across industries for quality assurance and regulatory compliance. Challenges in developing precise analytical techniques provide opportunities for service providers, while government initiatives encourage investment and innovation. These factors drive market expansion globally, alongside trends such as outsourcing due to pricing concerns and the development of innovative medicines. Expansion into new locations also boosts demand for specific tests, further driving the need for healthcare analytical testing services.

“Biohealthcare analytical testing services segment accounted for a substantial share of the healthcare analytical testing services market, by type in 2023.”
The Biohealthcare analytical testing services segment is expected to account for the largest share of 37.1% of the global Healthcare analytical testing services Market in 2023. It is projected to grow at the highest CAGR of 10.7% during the forecast period. The healthcare analytical testing services market is segmented by type into various categories, including bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, genomic services, and environmental monitoring services. In 2023, the biohealthcare analytical testing services segment stood out as the largest, primarily due to its comprehensive offerings tailored to different drug types like vaccines, small molecules, and biologics. This extensive range of services meets the diverse requirements of pharmaceutical and biopharmaceutical companies, thereby driving the segment's substantial market share.
“The cell-based assays segment accounted for the largest share in the healthcare analytical testing services market”
Based on bioanalytical service types type, the market encompasses cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and other biohealthcare analytical testing services. In 2023, the cell-based assays segment emerged as the market leader. This dominance is attributed to the growing preference for cell-based assays in high-throughput screening, as they offer pertinent in vivo biological insights compared to biochemical assays. This advantage accelerates the drug discovery process, thus contributing to the segment's prominence.


“North America to witness the substantial growth rate during the forecast period.”
North America commands the largest share in the healthcare analytical testing services market, outstripping other regions such as Europe, Asia Pacific, Latin America, and the Middle East & Africa. This dominance is primarily fueled by the burgeoning number of biopharmaceutical and pharmaceutical companies based in the United States. Moreover, the US market benefits from the strong foothold of well-established players, which further propels the market's growth trajectory. The region's advanced infrastructure, supportive regulatory environment, and emphasis on research and development also contribute significantly to its leadership position in the global healthcare analytical testing services market.
The break-down of primary participants is as mentioned below:
• By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
• By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%

Key Players in the Healthcare analytical testing services Market
The prominent players in the global healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Medpace Holdings, Inc. (US), LGC Limited (Cinven) (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), BioAgilytix Labs (US), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), and Syneos Health, INC (US).
Research Coverage:
The report analyzes the Healthcare analytical testing services Market and aims to estimate the market size and future growth potential of various market segments, based on type, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
 Analysis of Market Dynamics (Stringent regulatory landscape, growing focus on analytical testing of bilogics and biomilars, rising investments in pharma and biopharma R & D), restraints (Increasing Preassure on market players due to rising cost and market competition), opportunities (Adoption of new technologies, supporting government initiatives), and challenges (increasing need for improvement of sentsitivity of bioanalytical methods)
 Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new service launches in the Healthcare analytical testing services market.
 Market Development: Comprehensive information on the lucrative emerging markets, component, demographics , end-user, and region.
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 50
1.1 STUDY OBJECTIVES 50
1.2 MARKET DEFINITION 50
1.2.1 INCLUSIONS & EXCLUSIONS 51
1.2.2 MARKET SEGMENTATION 52
FIGURE 1 MARKETS COVERED 52
1.2.3 REGIONS COVERED 53
FIGURE 2 REGIONAL SEGMENTATION 53
1.2.4 YEARS CONSIDERED 53
1.3 CURRENCY CONSIDERED 54
1.4 LIMITATIONS 54
1.4.1 METHODOLOGY-RELATED LIMITATIONS 54
1.4.2 SCOPE-RELATED LIMITATIONS 54
1.5 STAKEHOLDERS 54
1.6 SUMMARY OF CHANGES 55
2 RESEARCH METHODOLOGY 56
2.1 RESEARCH DATA 56
2.2 RESEARCH METHODOLOGY DESIGN 56
FIGURE 3 RESEARCH DESIGN 56
2.2.1 SECONDARY RESEARCH 57
2.2.1.1 Key data from secondary sources 58
2.2.2 PRIMARY DATA 58
FIGURE 4 PRIMARY SOURCES 59
2.2.2.1 Key data from primary sources 60
2.2.2.2 Insights from primary experts 60
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 61
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 61
2.3 MARKET SIZE ESTIMATION METHODOLOGY 62
FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 62
FIGURE 8 REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION 63
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION 63
FIGURE 10 TOP-DOWN APPROACH 64
FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 65
FIGURE 12 CAGR PROJECTIONS 65
2.4 DATA TRIANGULATION PROCEDURE 67
FIGURE 13 DATA TRIANGULATION METHODOLOGY 67
2.5 MARKET SHARE ESTIMATION 68
2.6 STUDY ASSUMPTIONS 68
2.7 RISK ASSESSMENT 68
TABLE 1 RISK ASSESSMENT ANALYSIS 68
2.8 RECESSION IMPACT ANALYSIS 69
3 EXECUTIVE SUMMARY 70
FIGURE 14 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 70
FIGURE 15 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 71
FIGURE 16 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 72
FIGURE 17 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 73
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 74
4 PREMIUM INSIGHTS 75
4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW 75
FIGURE 19 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH 75
4.2 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2023) 76
FIGURE 20 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023 76
4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 77
FIGURE 21 CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 77
4.4 REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2022–2029) 78
FIGURE 22 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022–2029) 78
4.5 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029) 79
FIGURE 23 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 79
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
FIGURE 24 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80
5.2.1 DRIVERS 81
5.2.1.1 Stringent regulatory guidelines 81
5.2.1.2 Growing focus on analytical testing of biologics & biosimilars 82
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS 82
5.2.1.3 Increasing outsourcing of analytical testing by pharmaceutical & medical device companies 82
5.2.1.4 Increasing number of clinical trials 83
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004–2024) 83
FIGURE 26 PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024) 84
5.2.1.5 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry 84
FIGURE 27 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002–2022 84
5.2.1.6 Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing 85
TABLE 3 IMPACT ANALYSIS: DRIVERS 85
5.2.2 RESTRAINTS 86
5.2.2.1 Increasing pressure on market players due to rising costs and market competition 86
TABLE 4 IMPACT ANALYSIS: RESTRAINTS 86
5.2.3 OPPORTUNITIES 87
5.2.3.1 Adoption of new techniques and technologies 87
5.2.3.2 Growing focus on emerging economies 87
TABLE 5 IMPACT ANALYSIS: OPPORTUNITIES 88
5.2.4 CHALLENGES 88
5.2.4.1 Shortage of skilled professionals 88
5.2.4.2 Specific requirements for innovative formulations and medical devices 89
5.2.4.3 Need to improve sensitivity of bioanalytical methods 89
TABLE 6 IMPACT ANALYSIS: CHALLENGES 90
5.3 ECOSYSTEM ANALYSIS 90
TABLE 7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM 90
FIGURE 28 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM ANALYSIS 91
5.4 VALUE CHAIN ANALYSIS 91
FIGURE 29 VALUE CHAIN ANALYSIS 91
5.5 CASE STUDY ANALYSIS 92
5.5.1 UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING 92
5.5.2 REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION 92
5.6 PORTER’S FIVE FORCES ANALYSIS 92
TABLE 8 PORTER’S FIVE FORCES ANALYSIS 92
FIGURE 30 PORTER’S FIVE FORCES ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 93
5.6.1 THREAT OF NEW ENTRANTS 93
5.6.2 BARGAINING POWER OF SUPPLIERS 93
5.6.3 INTENSITY OF COMPETITIVE RIVALRY 94
5.6.4 BARGAINING POWER OF BUYERS 94
5.6.5 THREAT OF SUBSTITUTES 94
5.7 REGULATORY LANDSCAPE 95
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
5.7.2 REGULATORY ANALYSIS 96
TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS 97
TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES 98
5.7.3 NORTH AMERICA 98
5.7.4 EUROPE 99
TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES 99
TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES 99
5.7.5 ASIA PACIFIC 100
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
FIGURE 31 REVENUE SHIFT AND NEW POCKETS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 101
5.9 KEY CONFERENCES & EVENTS, 2024–2025 101
TABLE 18 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS 101
5.10 INVESTMENT AND FUNDING SCENARIO 102
FIGURE 32 NUMBER OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018–2022 102
FIGURE 33 VALUE OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022 103
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 103
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 103
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 104
5.11.2 BUYING CRITERIA 104
FIGURE 35 KEY BUYING CRITERIA FOR END USERS 104
TABLE 20 KEY BUYING CRITERIA FOR END USERS 105
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE 106
6.1 INTRODUCTION 107
TABLE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 107
6.2 BIOANALYTICAL TESTING 107
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 108
TABLE 23 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 108
6.2.1 PHARMACOKINETIC & TOXICOKINETIC TESTING 109
6.2.1.1 Increasing number of clinical trials for drug development to propel growth 109
TABLE 24 PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 109
6.2.2 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING 110
6.2.2.1 Increasing requirement for drug safety approvals to support market growth 110
TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 111
6.2.3 BIOMARKER TESTING 111
6.2.3.1 Rising need for specialized drug development to drive market 111
TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 112
6.2.4 BIOASSAY TESTING 112
6.2.4.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth 112
TABLE 27 BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 113
6.2.5 OTHER BIOANALYTICAL TESTING SERVICES 113
TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 114
6.3 PHYSICAL CHARACTERIZATION 114
TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 115
TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 115
6.3.1 LASER PARTICLE SIZE ANALYSIS 116
6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market 116
TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 116
6.3.2 THERMAL ANALYSIS 117
6.3.2.1 Advancements in thermal analysis techniques to support growth 117
TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 117
6.3.3 OPTICAL CHARACTERIZATION 117
6.3.3.1 Growing complexity of biological structures to contribute to growth 117
TABLE 33 OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 118
6.3.4 SURFACE AREA ANALYSIS 118
6.3.4.1 Growing need for surface analysis to streamline drug development processes to fuel growth 118
TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 119
6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES 119
TABLE 35 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 120
6.4 METHOD DEVELOPMENT & VALIDATION 120
TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 121
TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 121
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION 122
6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market 122
TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 122
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION 123
6.4.2.1 Rising emphasis on impurity testing to boost market 123
TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 123
6.4.3 STABILITY-INDICATING METHOD VALIDATION 124
6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth 124
TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 124
6.4.4 CLEANING VALIDATION & METHOD DEVELOPMENT 124
6.4.4.1 Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth 124
TABLE 41 CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 125
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION 125
6.4.5.1 Growing importance of analytical standard characterization in drug development to support market 125
TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 126
6.4.6 TECHNICAL CONSULTING 126
6.4.6.1 Need for regulatory approvals for drug development to drive market 126
TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 127
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES 127
TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 128
6.5 RAW MATERIAL TESTING 128
TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 129
TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 129
6.5.1 COMPLETE COMPENDIAL TESTING 129
6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth 129
TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 130
6.5.2 CONTAINER TESTING 130
6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth 130
TABLE 48 CONTAINER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 131
6.5.3 HEAVY METAL TESTING 131
6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth 131
TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 132
6.5.4 WATER CONTENT ANALYSIS 132
6.5.4.1 Need to check for water content in pharmaceutical products to support growth 132
TABLE 50 WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 133
6.5.5 OTHER RAW MATERIAL TESTING SERVICES 133
TABLE 51 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 133
6.6 BATCH-RELEASE TESTING SERVICES 134
TABLE 52 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 135
6.6.1 DISSOLUTION TESTING 135
6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth 135
TABLE 54 DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 136
6.6.2 ELEMENTAL IMPURITY TESTING 136
6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth 136
TABLE 55 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 137
6.6.3 DISINTEGRATION TESTING 137
6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth 137
TABLE 56 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA 138
TABLE 57 DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 138
6.6.4 HARDNESS TESTING 139
6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth 139
TABLE 58 HARDNESS TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 139
6.6.5 FRIABILITY TESTING 140
6.6.5.1 Need to measure resistance of tablets and granules to abrasion or fracture to support market 140
TABLE 59 FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 140
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES 140
TABLE 60 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 141
6.7 STABILITY TESTING 141
TABLE 61 STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 142
TABLE 62 STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 142
6.7.1 DRUG SUBSTANCE STABILITY TESTING 142
6.7.1.1 Regulatory requirements for drug approval to drive market 142
TABLE 63 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 143
6.7.2 FORMULATION EVALUATION STABILITY TESTING 143
6.7.2.1 Need to analyze and predict shelf life of products to drive demand 143
TABLE 64 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 144
6.7.3 ACCELERATED STABILITY TESTING 144
6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth 144
TABLE 65 ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 145
6.7.4 PHOTOSTABILITY TESTING 145
6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption 145
TABLE 66 PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 146
6.7.5 FORCED DEGRADATION TESTING 146
6.7.5.1 Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market 146
TABLE 67 FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 147
6.7.6 OTHER STABILITY TESTING SERVICES 147
TABLE 68 OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 147
6.8 MICROBIAL TESTING 148
TABLE 69 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 148
TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 149
6.8.1 MICROBIAL LIMIT TESTING 149
6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption 149
TABLE 71 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING 150
TABLE 72 MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 150
6.8.2 VIROLOGY TESTING 150
6.8.2.1 Increasing outbreaks of viral diseases to drive market 150
TABLE 73 VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 151
6.8.3 STERILITY TESTING 151
6.8.3.1 Rising development of parenteral preparations and immunological products to drive market 151
TABLE 74 STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 152
6.8.4 ENDOTOXIN TESTING 152
6.8.4.1 Need to standardize procedures and follow regulatory guidelines to support demand 152
TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 153
6.8.5 PRESERVATIVE EFFICACY TESTING 153
6.8.5.1 Need to ensure product safety for product approval to support growth 153
TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 154
6.8.6 OTHER MICROBIAL TESTING SERVICES 154
TABLE 77 OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 155
6.9 GENOMIC TESTING SERVICES 155
6.9.1 NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET 155
TABLE 78 GENOMIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 156
6.10 OTHER ANALYTICAL TESTING SERVICES 156
TABLE 79 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 156
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER 157
7.1 INTRODUCTION 158
TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 158
7.2 PHARMACEUTICAL COMPANIES 158
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH 158
FIGURE 36 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020–2022 159
TABLE 81 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION) 160
7.3 BIOPHARMACEUTICAL COMPANIES 160
7.3.1 GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH 160
TABLE 82 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION) 161
7.4 MEDICAL DEVICE COMPANIES 161
7.4.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH 161
TABLE 83 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION) 162
7.5 HOSPITALS & CLINICS 162
7.5.1 GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH 162
TABLE 84 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION) 163
7.6 FORENSIC LABS 163
7.6.1 GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH 163
TABLE 85 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR FORENSIC LABS, BY REGION, 2022–2029 (USD MILLION) 164
7.7 COSMETIC & NUTRACEUTICAL COMPANIES 164
7.7.1 STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET 164
TABLE 86 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION) 165
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION 166
8.1 INTRODUCTION 167
FIGURE 37 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT 167
TABLE 87 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 168
8.2 NORTH AMERICA 168
8.2.1 NORTH AMERICA: RECESSION IMPACT 168
FIGURE 38 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 169
TABLE 88 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 89 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 90 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 91 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 92 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 93 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 94 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 95 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 96 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 97 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 174
8.2.2 US 175
8.2.2.1 High number of pre-registration drugs in pipeline to drive market 175
FIGURE 39 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021) 175
TABLE 98 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 99 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 100 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 101 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 102 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 103 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 104 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 105 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 179
8.2.3 CANADA 180
8.2.3.1 Presence of well-established CROs to support market growth 180
FIGURE 40 CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023) 180
TABLE 106 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 107 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 108 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 109 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 110 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 111 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 112 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 113 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
8.3 EUROPE 185
8.3.1 EUROPE: RECESSION IMPACT 185
TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 115 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 116 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 117 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 118 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 119 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 120 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 121 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 122 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 190
8.3.2 GERMANY 191
8.3.2.1 Government support and flexible labor laws make Germany favorable location for clinical trials 191
TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 195
8.3.3 FRANCE 196
8.3.3.1 Favorable government regulations to drive market 196
TABLE 132 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 133 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 134 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 135 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 136 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 137 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 138 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 139 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 200
8.3.4 UK 201
8.3.4.1 Investments by pharmaceutical sponsors for drug discovery services to support growth 201
TABLE 140 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 141 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 142 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 143 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 144 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 145 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 146 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 147 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 205
8.3.5 ITALY 205
8.3.5.1 Low drug approval time to support market growth 205
TABLE 148 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 149 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 150 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 151 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 152 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 153 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 154 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 155 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 209
8.3.6 SWITZERLAND 210
8.3.6.1 Large and growing pharma production volume to drive demand for analytical testing services 210
TABLE 156 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 157 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 158 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 159 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 160 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 161 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 162 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 163 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 214
8.3.7 SPAIN 214
8.3.7.1 Rising R&D expenditure to boost growth 214
TABLE 164 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 165 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 166 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 167 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 168 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 169 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 170 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 171 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 218
8.3.8 REST OF EUROPE 219
TABLE 172 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 173 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 174 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 175 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 176 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 177 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 178 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 179 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
8.4 ASIA PACIFIC 224
8.4.1 ASIA PACIFIC: RECESSION IMPACT 224
FIGURE 41 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT 225
TABLE 180 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 181 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 182 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 183 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 184 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 185 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 186 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 187 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 188 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 189 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 230
8.4.2 CHINA 231
8.4.2.1 Low manufacturing cost of medicines to drive demand 231
TABLE 190 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 191 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 192 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 193 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 194 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 195 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 196 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 197 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 235
8.4.3 JAPAN 235
8.4.3.1 Rising geriatric population to support market growth 235
TABLE 198 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 199 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 200 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 201 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 202 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 203 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 204 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 205 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 240